跳轉至內容
Merck
  • Discovery and structure-activity study of a novel benzoxaborole anti-inflammatory agent (AN2728) for the potential topical treatment of psoriasis and atopic dermatitis.

Discovery and structure-activity study of a novel benzoxaborole anti-inflammatory agent (AN2728) for the potential topical treatment of psoriasis and atopic dermatitis.

Bioorganic & medicinal chemistry letters (2009-03-24)
Tsutomu Akama, Stephen J Baker, Yong-Kang Zhang, Vincent Hernandez, Huchen Zhou, Virginia Sanders, Yvonne Freund, Richard Kimura, Kirk R Maples, Jacob J Plattner
摘要

A series of phenoxy benzoxaboroles were synthesized and screened for their inhibitory activity against PDE4 and cytokine release. 5-(4-Cyanophenoxy)-2,3-dihydro-1-hydroxy-2,1-benzoxaborole (AN2728) showed potent activity both in vitro and in vivo. This compound is now in clinical development for the topical treatment of psoriasis and being pursued for the topical treatment of atopic dermatitis.

材料
產品編號
品牌
產品描述

Sigma-Aldrich
地塞米松, powder, BioReagent, suitable for cell culture, ≥97%
Sigma-Aldrich
地塞米松, ≥98% (HPLC), powder
Sigma-Aldrich
地塞米松, powder, γ-irradiated, BioXtra, suitable for cell culture, ≥80% (HPLC)
Sigma-Aldrich
地塞米松, meets USP testing specifications
Sigma-Aldrich
Crisaborole, ≥98% (HPLC)
Sigma-Aldrich
地塞米松, tested according to Ph. Eur.
Supelco
地塞米松, VETRANAL®, analytical standard